Biology and clinical implications of CD133+ liver cancer stem cells

Experimental Cell Research

Volumn 319, Issue 2, 2013, Pages 126-132

  Ma, Stephanie ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer stem cells; Cancer initiating cells; CD133; Liver cancer; Recurrence; Self renewal

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; BMI1 PROTEIN; CD133 ANTIGEN; CYTOCHROME P450 3A4; CYTOKERATIN 19; MICRORNA; SORAFENIB;

ANTIGEN EXPRESSION; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE ARREST; CLONOGENESIS; COLONY FORMATION; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS C; LIVER CANCER; LIVER CARCINOGENESIS; LIVER REGENERATION; LIVER TRANSPLANTATION; LUNG METASTASIS; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 84870751884     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.09.007     Document Type: Review

References (33)

1. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K., Buck D.W. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
2. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., Olweus J., Kearney J., Buck D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
3. Mizrak D., Brittan M., Alison M.R. CD133: molecule of the moment. J. Pathol. 2008, 214:3-9.
4. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-513.
5. Chiba T., Kita K., Zheng Y.W., Yokosuka O., Saisho H., Iwama A., Nakauchi H., Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
6. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
7. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:144-150.
8. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., Zheng B.J., Guan X.Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
9. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., Ng I., Man K., Wong N., To K.F., Zheng B.J., Lai P.B., Lo C.M., Chan K.W., Guan X.Y. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
10. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
11. Piao L.S., Hur W., Kim T.K., Hong S.W., Kim S.W., Choi E., Sung P.S., Song M.J., Lee B.C., Hwang D., Yoon S.K. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012, 315:129-137.
12. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., Jia H., Ye Q., Qin L.X., Wautheir E., Reid L.M., Minato H., Honda M., Kaneko S., Tang Z.Y., Wang X.W. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
13. Zhu Z., Hao X., Yan M., Yao M., Ge C., Gu J., Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126:2067-2078.
14. Hou Y., Zou Q., Ge R., Shen F., Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012, 22:259-272.
15. Tang K.H., Ma S., Lee T.K., Chan Y.P., Kwan P.S., Tong C.M., Ng I.O., Man K., To K.F., Lai P.B., Lo C.M., Guan X.Y., Chan K.W. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012, 55:807-820.
16. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9:50-63.
17. Song W., Li H., Tao K., Li R., Song Z., Zhao Q., Zhang F., Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 2008, 62:1212-1218.
18. Sasaki A., Kamiyama T., Yokoo H., Nakanishi K., Kubota K., Haga H., Matsushita M., Ozaki M., Matsuno Y., Todo S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010, 24:537-546.
19. Ma S., Chan K.W., Lee T.K., Tang K.H., Wo J.Y., Zheng B.J., Guan X.Y. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008, 6:1146-1153.
20. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 2006, 103:10544-10551.
21. Hagiwara S., Kudo M., Nagai T., Inoue T., Ueshima K., Nishida N., Watanabe T., Sakurai T. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br. J. Cancer 2012, 106:1997-2003.
22. Yang Z., Zhang L., Ma A., Liu L., Li J., Gu J., Liu Y. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 2011, 6:e28405.
23. Zhang L., Sun H., Zhao F., Lu P., Ge C., Li H., Hou H., Yan M., Chen T., Jiang G., Xie H., Cui Y., Huang X., Fan J., Yao M., Li J. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 2012, (Epub ahead of print).
24. Kohga K., Tatsumi T., Takehara T., Tsunematsu H., Shimizu S., Yamamoto M., Sasakawa A., Miyagi T., Hayashi N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 2010, 52:872-879.
25. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
26. Zhang C., Xu Y., Zhao J., Fan L., Jiang G., Li R., Ling Y., Wu M., Wei L. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. Ann. Surg. Oncol. 2011, 18:2372-2380.
27. Zhang J., Luo N., Luo Y., Peng Z., Zhang T., Li S. MicroRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int. J. Oncol. 2012, 40:747-756.
28. Ali N., Allam H., May R., Sureban S.M., Bronze M.S., Bader T., Umar S., Anant S., Houchen C.W. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J. Virol. 2011, 85:12292-12303.
29. Arzumanyan A., Friedman T., Ng I.O., Clayton M.M., Lian Z., Feitelson M.A. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?. Cancer Res. 2011, 71:3701-3708.
30. Ma N.F., Lau S.H., Hu L., Xie D., Wu J., Yang J., Wang Y., Wu M.C., Fung J., Bai X., Tzang C.H., Fu L., Yang M., Su Y.A., Guan X.Y. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin. Cancer Res. 2008, 14:5061-5068.
31. Sze K.M., Chu G.K., Lee J.M., Ng I.O. C-terminal truncated HBx is associated with metastasis and enhances invasiveness via C-Jun/MMP10 activation in hepatocellular carcinoma. Hepatology 2012, 10.1002/hep.25979.
32. Yeh C.T., Kuo C.J., Lai M.W., Chen T.C., Lin C.Y., Yeh T.S., Lee W.C. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009, 9:324.
33. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53:160-170.